Supplementary Online Content

Cao Y, Nishihara R, Wu K, et al. Population-wide impact of long-term use of aspirin and the risk for cancer. *JAMA Oncol*. Published online March 3, 2016. doi:10.1001/jamaoncol.2015.6396.

This supplementary material has been provided by the authors to give readers additional information about their work.

eMethods. Statistical Analysis

At baseline, we excluded participants with cancer or who reported implausible energy intakes (<600 or >3500 kcal/d for women and <800 or >4200 kcal/d for men). Because most prostate cancer detected through prostate-specific antigen (PSA) screening is indolent, we included only advanced cases defined as regionally invasive, metastatic (≥T3b, N1 or M1) at diagnosis, or cases that developed metastases or died from prostate cancer during follow-up.[1]

The covariates included in the multivariable models were established/potential risk factors for major cancers, including race, height, BMI, family history of cancer, physical exam in past 2 years, history of colonoscopy/sigmoidoscopy, pack-years of smoking, leisure-time physical activity, alcohol intake, current multivitamin use, regular use of nonsteroidal anti-inflammatory drugs, total energy intake, folate, calcium, red and processed meat intake, and adherence to Alternate Health Eating Index (AHEI)-2010.[2,3] Among men, we also adjusted for PSA test; among women, we also adjusted for menopause status/menopausal hormone therapy (MHT), and mammography in past 2 years.

Departures from the proportional hazards assumption was tested by likelihood ratio tests comparing models with and without the interaction terms of age or follow-up cycle by aspirin exposures. No significant violation of proportionality was found (P>0.05). We suspended update of aspirin information after a confirmed diagnosis of gastrointestinal bleeding since this is likely to alter aspirin use.

For missing data on aspirin use, we carry forward from the previous questionnaire and conducted sensitivity analysis to compare the estimates; for missing data on covariates, we used indicator variable to represent the missing category.

As a sensitivity analysis, we evaluated the latency of aspirin dose and risk of cancer using a lag of 6-8 years. For example, in NHS, we used aspirin dose in 1980 for cases diagnosed in 1986-1988, intake in 1982 for cases diagnosed in 1988-1990, and so forth.

eReferences

1. Wilson KM, Kasperzyk JL, Rider JR, et al. Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. *J Natl Cancer Inst.* 2011;103(11):876-884.
2. McCullough ML, Feskanich D, Stampfer MJ, et al. Diet quality and major chronic disease risk in men and women: moving toward improved dietary guidance. *Am J Clin Nutr.* 2002;76(6):1261-1271.
3. Chiuve SE, Fung TT, Rimm EB, et al. Alternative Dietary Indices Both Strongly Predict Risk of Chronic Disease. *J Nutr.* 2012;142(6):1009-1018.

eTable 1. Age-Standardized Characteristics According to Person-years of Regular Aspirin Use

Characteristic	NHS		HPFS	
	Nonregular user	Regular user	Nonregular user	Regular user
Age, y[a]	58.4(10.8)	62.4(11.3)	61.0(11.0)	64.8(10.3)
White, %	97	98	89	91
Family history of cancer, %	38	38	25	28
History of diabetes, %	6.0	7.9	6.0	7.9
Hypertension, %	34	42	31	42
Hypercholesterolemia, %	37	43	34	49
≥2 cardiac risk factors[b], %	30	38	22	34
Height, cm	164(6)	164(6)	178(7)	178(7)
BMI, kg/m²	25.1(4.5)	25.5(4.7)	25.7(3.4)	26.0(3.4)
Postmenopause, %	75	78	-	-
Current hormone therapy use, %	27	30	-	-
Physical examination in past 2 y, %	70	75	72	80
History of colonoscopy/sigmoidoscopy, %	35	39	46	55
Mammogram in past 2 y, %	70	75	-	-
Prostate-specific antigen (PSA) test in past 2 y, %	-	-	26	39
Current use of multivitamin, %	47	56	39	53
Regular use of NSAIDs, %	29	28	13	17
Physical activity, MET-hrs/wk	16.3(18.0)	16.9(16.8)	29.2(29.4)	30.5(28.7)
Ever smokers, %	55	56	49	53
Pack-years among ever smokers	23.5(20.0)	23.8(20.3)	24.4(19.1)	24.8(18.9)
Total calorie intake, kcal/d	1667(441)	1691(445)	1968(567)	1990(554)
Alcohol intake, g/d	5.9(9.3)	6.3(9.5)	10.4(13.8)	11.7(14.1)
Red and processed meat intake, servings/wk	6.6(3.7)	6.8(3.7)	6.5(4.6)	6.3(4.4)
Folate intake, µg/d	409(216)	431(210)	512(255)	554(249)
Calcium intake, mg/d	904(349)	932(356)	913(381)	938(366)
Alternate Healthy Eating Index (AHEI) 2010[c]	46.1(9.8)	46.0(9.5)	47.7(10.3)	48.2(9.9)

[a]All values other than age have been directly standardized to age distribution (in 5-year age group) of all the participants. Mean (SD) was presented for continuous variables.
[b]Includes hypertension, hypercholesterolemia, diabetes mellitus, current smoking, and BMI≥30 kg/m^2.
[c]Without alcohol intake.

eTable 2. Regular Aspirin Use and Risk for Other Cancer

	Regular user vs nonregular user		
	Women	**Men**	**Combined**
Endometrial			
Cases, No.	616/855	-	
Age-adjusted RR (95% CI)	1.02 (0.92, 1.13)	-	
Multivariable RR (95% CI)[a]	0.97 (0.87, 1.08)	-	
Ovarian			
Cases, No.	334/452	-	
Age-adjusted RR (95% CI)	1.05 (0.90, 1.21)	-	
Multivariable RR (95% CI)[a]	1.05 (0.90, 1.21)	-	
Kidney			
Cases, No.	162/175	147/152	309/327
Age-adjusted RR (95% CI)	1.10 (0.88, 1.36)	0.96 (0.76, 1.21)	1.03 (0.88, 1.21)
Multivariable RR (95% CI)[a]	1.03 (0.83, 1.29)	0.94 (0.74, 1.19)	0.99 (0.84, 1.16)
Bladder			
Cases, No.	222/233	383/311	605/544
Age-adjusted RR (95% CI)	1.17 (0.97, 1.42)	1.19 (1.02, 1.38)	1.18 (1.05, 1.33)
Multivariable RR (95% CI)[a]	1.11 (0.92, 1.35)	1.08 (0.92, 1.26)	1.09 (0.97, 1.23)
Brain			
Cases, No.	57/89	82/82	139/171
Age-adjusted RR (95% CI)	0.96 (0.68, 1.35)	1.02 (0.74, 1.41)	0.99 (0.79, 1.25)
Multivariable RR (95% CI)[a]	0.95 (0.67, 1.34)	1.10 (0.79, 1.53)	1.03 (0.81, 1.30)
Melanoma			
Cases, No.	562/608	400/391	972/999
Age-adjusted RR (95% CI)	0.96 (0.68, 1.35)	1.02 (0.88, 1.18)	1.09 (1.00, 1.20)
Multivariable RR (95% CI)[a]	0.95 (0.67, 1.34)	0.97 (0.84, 1.12)	1.04 (0.95, 1.14)
Non-Hodgkin's lymphoma			
Cases, No.	467/571	343/295	810/866
Age-adjusted RR (95% CI)	1.15 (1.02, 1.29)	1.11 (0.94, 1.30)	1.03 (0.93, 1.14)
Multivariable RR (95% CI)[a]	1.09 (0.96, 1.22)	1.07 (0.91, 1.26)	0.99 (0.89, 1.09)
Myeloma			
Cases, No.	91/105	84/91	175/196
Age-adjusted RR (95% CI)	0.98 (0.87, 1.11)	0.86 (0.63, 1.16)	0.97 (0.79, 1.19)
Multivariable RR (95% CI)[a]	0.94 (0.83, 1.07)	0.86 (0.63, 1.17)	0.96 (0.77, 1.18)
Leukemia			
Cases, No.	73/83	119/154	192/237
Age-adjusted RR (95% CI)	1.11 (0.81, 1.54)	0.71 (0.56, 0.91)	0.84 (0.69, 1.02)
Multivariable RR (95% CI)[a]	1.10 (0.80, 1.53)	0.70 (0.54, 0.89)	0.82 (0.68, 1.01)

NHS 1980-2012, HPFS 1986-2010

[a]Adjusted for the same variables as in Table 2.

eTable 3. Dose of Standard Aspirin and Risk for Cancer by Sex

	Tablets/wk					P value for trend[c]
	0	0.5-1.5	2-5	6-14	≥15	
Total cancer[a]						
Women						
Cases, No. (N=20358)	10129	2783	4089	2750	607	
Person-years	1158258	352842	451999	283483	78897	
Age-adjusted RR (95% CI)	1[Reference]	0.96 (0.92, 1.01)	0.97 (0.94, 1.01)	1.01 (0.97, 1.06)	1.03 (0.95, 1.12)	.30
Multivariable RR (95% CI)[b]	1[Reference]	0.98 (0.94, 1.02)	0.97 (0.93, 1.00)	0.97 (0.93, 1.01)	1.00 (0.92, 1.09)	.40
Men						
Cases, No. (N=5429)	2191	883	1332	901	122	
Person-years	229903	104111	139279	94388	12858	
Age-adjusted RR (95% CI)	1[Reference]	0.94 (0.87, 1.02)	0.96 (0.89, 1.03)	0.92 (0.85, 0.99)	0.96 (0.80, 1.15)	.10
Multivariable RR (95% CI)[b]	1[Reference]	0.94 (0.87, 1.02)	0.94 (0.88, 1.01)	0.88 (0.81, 0.95)	0.89 (0.74, 1.07)	.003
GI cancer						
Women						
Cases, No. (N=2370)	1247	319	435	307	62	
Age-adjusted RR (95% CI)	1[Reference]	0.85 (0.75, 0.97)	0.87 (0.78, 0.97)	0.86 (0.76, 0.98)	0.78 (0.60, 1.01)	.02
Multivariable RR (95% CI)[b]	1[Reference]	0.87 (0.77, 0.99)	0.88 (0.79, 0.98)	0.83 (0.73, 0.94)	0.76 (0.59, 0.99)	.003
Men						
Cases, No. (N=1357)	581	223	305	228	20	
Age-adjusted RR (95% CI)	1[Reference]	0.92 (0.78, 1.07)	0.81 (0.71, 0.94)	0.86 (0.74, 1.01)	0.60 (0.38, 0.94)	.009
Multivariable RR (95% CI)[b]	1[Reference]	0.91 (0.78, 1.07)	0.82 (0.71, 0.95)	0.82 (0.70, 0.96)	0.56 (0.35, 0.87)	.001
Non-GI cancer						
Women						
Cases, No. (N=17988)	8882	2464	3654	2443	545	
Age-adjusted RR (95% CI)	1[Reference]	0.98 (0.93, 1.02)	0.99 (0.95, 1.03)	1.04 (0.99, 1.08)	1.07 (0.98, 1.17)	.05
Multivariable RR (95% CI)[b]	1[Reference]	0.99 (0.95, 1.04)	0.98 (0.94, 1.02)	0.99 (0.95, 1.04)	1.03 (0.95, 1.13)	.83
Men						
Cases, No. (N=4072)	1610	660	1027	673	102	
Age-adjusted RR (95% CI)	1[Reference]	0.95 (0.87, 1.04)	1.01 (0.93, 1.09)	0.94 (0.86, 1.03)	1.09 (0.89, 1.34)	.71
Multivariable RR (95% CI)[b]	1[Reference]	0.94 (0.86, 1.04)	0.99 (0.91, 1.07)	0.90 (0.82, 0.98)	1.01 (0.82, 1.24)	.13

NHS 1980-2012, HPFS 1992-2010

[a]For prostate cancer, only advanced cases were included.

[b]Adjusted for the same variables as in Table 2.

[c]Tests for trend were conducted using the median value of each category as a continuous variable.

eTable 4. Dose of Standard Aspirin (With 6- to 8-Year Lag) and Risk for Cancer

	Tablets/wk					P value for trend[c]
	0	0.5-1.5	2-5	6-14	≥15	
Total cancer[a]						
Women						
Cases, No. (N=14140)	7032	2297	2352	1964	495	
Person-years	681338	240793	237947	175236	52388	
Age-adjusted RR (95% CI)	1[Reference]	0.97 (0.92, 1.02)	0.98 (0.94, 1.03)	1.01 (0.96, 1.07)	1.01 (0.92, 1.11)	.46
Multivariable RR (95% CI)[b]	1[Reference]	0.98 (0.93, 1.03)	0.98 (0.94, 1.03)	0.98 (0.93, 1.03)	0.99 (0.90, 1.08)	.60
Men						
Cases, No. (N=2865)	1046	539	683	540	57	
Person-years	110055	57439	65750	52516	6119	
Age-adjusted RR (95% CI)	1[Reference]	1.00 (0.90, 1.11)	1.03 (0.93, 1.13)	0.97 (0.88, 1.08)	0.92 (0.70, 1.20)	.41
Multivariable RR (95% CI)[b]	1[Reference]	1.00 (0.90, 1.11)	1.02 (0.92, 1.13)	0.92 (0.83, 1.03)	0.86 (0.65, 1.12)	.06
Combined						
Cases, No. (N=17005)	8078	2836	3035	2504	552	
Person-years	791393	298232	303697	227752	58507	
Age-adjusted RR (95% CI)	1[Reference]	0.97 (0.93, 1.02)	0.99 (0.95, 1.03)	1.00 (0.96, 1.05)	1.00 (0.92, 1.10)	.68
Multivariable RR (95% CI)[b]	1[Reference]	0.99 (0.94, 1.03)	0.99 (0.95, 1.04)	0.97 (0.93, 1.02)	0.98 (0.89, 1.07)	.28
GI cancer						
Women						
Cases, No. (N=1616)	871	251	246	198	50	
Age-adjusted RR (95% CI)	1[Reference]	0.78 (0.68, 0.91)	0.82 (0.71, 0.94)	0.77 (0.66, 0.91)	0.71 (0.53, 0.95)	.002
Multivariable RR (95% CI)[b]	1[Reference]	0.79 (0.68, 0.92)	0.83 (0.72, 0.96)	0.76 (0.65, 0.89)	0.71 (0.53, 0.95)	.001
Men						
Cases, No. (N=723)	279	136	174	124	10	
Age-adjusted RR (95% CI)	1[Reference]	0.95 (0.77, 1.17)	0.97 (0.80, 1.18)	0.83 (0.67, 1.03)	0.60 (0.32, 1.13)	.02
Multivariable RR (95% CI)[b]	1[Reference]	0.97 (0.78, 1.19)	0.99 (0.81, 1.21)	0.79 (0.63, 0.98)	0.57 (0.30, 1.08)	.006
Combined						
Cases, No. (N=2339)	1150	387	420	322	60	
Age-adjusted RR (95% CI)	1[Reference]	0.83 (0.74, 0.94)	0.87 (0.77, 0.97)	0.79 (0.69, 0.89)	0.69 (0.53, 0.90)	<.001
Multivariable RR (95% CI)[b]	1[Reference]	0.85 (0.75, 0.95)	0.88 (0.79, 0.99)	0.77 (0.68, 0.87)	0.69 (0.53, 0.90)	<.001
Non-GI cancer						
Women						
Cases, No. (N=12524)	6161	2046	2106	1766	445	
Age-adjusted RR (95% CI)	1[Reference]	1.00 (0.95, 1.05)	1.01 (0.96, 1.06)	1.05 (0.99, 1.11)	1.06 (0.96, 1.17)	.05
Multivariable RR (95% CI)[b]	1[Reference]	1.01 (0.96, 1.06)	1.00 (0.96, 1.06)	1.01 (0.96, 1.07)	1.03 (0.93, 1.14)	.53
Men						
Cases, No. (N=2147)	767	403	509	416	47	
Age-adjusted RR (95% CI)	1[Reference]	1.02 (0.90, 1.15)	1.05 (0.93, 1.18)	1.03 (0.91, 1.16)	1.04 (0.77, 1.40)	.69
Multivariable RR (95% CI)[b]	1[Reference]	1.01 (0.89, 1.14)	1.02 (0.91, 1.15)	0.97 (0.86, 1.10)	0.95 (0.70, 1.29)	.50
Combined						

Cases, No. (N=14666)	6928	2449	2615	2182	492	
Age-adjusted RR (95% CI)	1[Reference]	1.00 (0.95, 1.05)	1.01 (0.97, 1.06)	1.04 (0.99, 1.10)	1.06 (0.97, 1.16)	.05
Multivariable RR (95% CI)[b]	1[Reference]	1.01 (0.96, 1.06)	1.01 (0.96, 1.06)	1.01 (0.96, 1.06)	1.03 (0.93, 1.13)	.65

NHS 1986-2012, HPFS 1998-2010

[a]For prostate cancer, only advanced cases were included.

[b]Adjusted for the same variables as in Table 2.

[c]Tests for trend were conducted using the median value of each category as a continuous variable.

eTable 5. Duration of Regular Aspirin Use and Risk for Cancer by Sex

	Years of Regular Aspirin Use					P value for trend[c]
	0	1-5	6-10	11-15	≥16	
Total cancer[a]						
Women						
Cases, No. (N=20335)	6307	3613	3418	1817	5180	
Person-years	861597	414034	328019	175455	542507	
Age-adjusted RR (95% CI)	1[Reference]	1.04 (1.00, 1.09)	1.06 (1.01, 1.11)	1.05 (0.99, 1.10)	1.00 (1.00, 1.00)	.24
Multivariable RR (95% CI)[b]	1[Reference]	1.01 (0.97, 1.06)	1.02 (0.98, 1.07)	1.01 (0.96, 1.07)	0.96 (0.92, 1.00)	.01
Men						
Cases, No. (N=7571)	2432	1509	1772	830	1028	
Person-years	343395	184589	196551	82600	98958	
Age-adjusted RR (95% CI)	1[Reference]	0.97 (0.91, 1.04)	0.94 (0.88, 1.00)	0.95 (0.87, 1.03)	0.95 (0.88, 1.03)	.13
Multivariable RR (95% CI)[b]	1[Reference]	0.95 (0.89, 1.02)	0.91 (0.85, 0.97)	0.90 (0.83, 0.98)	0.90 (0.83, 0.98)	.003
GI cancer						
Women						
Cases, No. (N=2366)	840	449	379	189	509	
Age-adjusted RR (95% CI)	1[Reference]	0.96 (0.85, 1.08)	0.87 (0.77, 0.98)	0.80 (0.68, 0.94)	0.76 (0.67, 0.85)	<.001
Multivariable RR (95% CI)[b]	1[Reference]	0.95 (0.84, 1.06)	0.86 (0.76, 0.98)	0.80 (0.68, 0.94)	0.76 (0.67, 0.85)	<.001
Men						
Cases, No. (N=1917)	655	386	436	194	246	
Age-adjusted RR (95% CI)	1[Reference]	0.92 (0.81, 1.04)	0.83 (0.74, 0.95)	0.78 (0.66, 0.93)	0.80 (0.68, 0.95)	.001
Multivariable RR (95% CI)[b]	1[Reference]	0.93 (0.82, 1.06)	0.85 (0.74, 0.97)	0.78 (0.66, 0.93)	0.79 (0.66, 0.93)	.001
Non-GI cancer						
Women						
Cases, No. (N=17969)	5467	3164	3039	1628	4671	
Age-adjusted RR (95% CI)	1[Reference]	1.06 (1.01, 1.10)	1.09 (1.04, 1.14)	1.09 (1.03, 1.15)	1.03 (0.99, 1.07)	.60
Multivariable RR (95% CI)[b]	1[Reference]	1.02 (0.98, 1.07)	1.05 (1.00, 1.10)	1.04 (0.98, 1.10)	0.99 (0.95, 1.03)	.24
Men						
Cases, No. (N=5654)	1777	1123	1336	636	782	
Age-adjusted RR (95% CI)	1[Reference]	1.00 (0.92, 1.08)	0.98 (0.91, 1.05)	1.02 (0.92, 1.12)	1.01 (0.92, 1.11)	.82
Multivariable RR (95% CI)[b]	1[Reference]	0.96 (0.89, 1.04)	0.93 (0.86, 1.00)	0.95 (0.86, 1.04)	0.94 (0.85, 1.04)	.15

NHS 1986-2012, HPFS 1998-2010

[a]For prostate cancer, only advanced cases were included.

[b]Adjusted for the same variables as in Table 2.

[c]Tests for trend were conducted using the median value of each category as a continuous variable.

eTable 6. Status, Duration of Regular Aspirin Use, and Time Since Last Use and Risk for Cancer

	Never regular user	Former regular user			Current regular user	
		≤10 y	> 10 y		≤10 y	>10 y
			>5 y since last use	≤5 y since last use		
Total cancer[a]						
Women						
Cases, No. (N=20335)	6307	3236	608	1280	3853	5051
Person-years	861597	334672	60238	139117	413703	512285
Age-adjusted RR (95% CI)	1[Reference]	1.05 (1.01, 1.10)	1.03 (0.94, 1.12)	1.02 (0.96, 1.09)	1.04 (1.00, 1.09)	1.00 (0.96, 1.04)
Multivariable RR (95% CI)[b]	1[Reference]	1.03 (0.98, 1.07)	0.98 (0.90, 1.07)	0.99 (0.93, 1.05)	1.01 (0.97, 1.05)	0.97 (0.93, 1.01)
Men						
Cases, No. (N=7571)	2432	1129	27	184	2386	1413
Person-years	343395	120438	1657	17429	288293	134886
Age-adjusted RR (95% CI)	1[Reference]	1.00 (0.93, 1.07)	1.44 (0.98, 2.13)	0.90 (0.77, 1.05)	0.93 (0.88, 0.99)	0.98 (0.91, 1.06)
Multivariable RR (95% CI)[b]	1[Reference]	0.97 (0.90, 1.05)	1.34 (0.91, 1.98)	0.85 (0.73, 1.00)	0.90 (0.85, 0.96)	0.93 (0.86, 1.01)
Combined						
Cases, No. (N=27906)	8739	4365	635	1464	6239	6464
Person-years	1204992	455110	61895	156546	701996	647171
Age-adjusted RR (95% CI)	1[Reference]	1.04 (1.00, 1.08)	1.03 (0.95, 1.12)	1.00 (0.95, 1.06)	1.00 (0.97, 1.04)	0.99 (0.96, 1.03)
Multivariable RR (95% CI)[b]	1[Reference]	1.01 (0.98, 1.05)	0.98 (0.90, 1.07)	0.96 (0.91, 1.02)	0.97 (0.94, 1.01)	0.96 (0.93, 0.99)
GI cancer						
Women						
Cases, No. (N=2366)	840	392	62	116	442	514
Age-adjusted RR (95% CI)	1[Reference]	0.96 (0.85, 1.08)	0.86 (0.66, 1.12)	0.72 (0.59, 0.87)	0.88 (0.78, 0.99)	0.78 (0.69, 0.87)
Multivariable RR (95% CI)[b]	1[Reference]	0.96 (0.85, 1.08)	0.86 (0.66, 1.12)	0.72 (0.59, 0.88)	0.86 (0.77, 0.97)	0.77 (0.69, 0.87)
Men						
Cases, No. (N=1917)	655	315	5	40	581	321
Age-adjusted RR (95% CI)	1[Reference]	1.01 (0.87, 1.16)	0.96 (0.39, 2.36)	0.70 (0.51, 0.98)	0.83 (0.74, 0.93)	0.79 (0.68, 0.91)
Multivariable RR (95% CI)[b]	1[Reference]	1.03 (0.89, 1.19)	0.98 (0.40, 2.41)	0.73 (0.52, 1.02)	0.82 (0.73, 0.93)	0.80 (0.68, 0.93)
Combined						
Cases, No. (N=4283)	1495	707	67	156	1023	835
Age-adjusted RR (95% CI)	1[Reference]	0.98 (0.89, 1.07)	0.87 (0.67, 1.11)	0.71 (0.60, 0.84)	0.85 (0.78, 0.92)	0.78 (0.71, 0.85)
Multivariable RR (95% CI)[b]	1[Reference]	0.99 (0.90, 1.08)	0.86 (0.67, 1.11)	0.72 (0.60, 0.85)	0.84 (0.77, 0.91)	0.78 (0.71, 0.86)
Non-GI cancer						
Women						
Cases, No. (N=17969)	5467	2844	546	1164	3411	4537
Age-adjusted RR (95% CI)	1[Reference]	1.07 (1.02, 1.12)	1.05 (0.96, 1.15)	1.07 (1.01, 1.14)	1.07 (1.02, 1.12)	1.04 (1.00, 1.08)
Multivariable RR (95% CI)[b]	1[Reference]	1.04 (0.99, 1.09)	1.00 (0.91, 1.09)	1.02 (0.96, 1.09)	1.03 (0.99, 1.08)	1.00 (0.96, 1.04)
Men						
Cases, No. (N=5654)	1777	814	22	144	1805	1092
Age-adjusted RR (95% CI)	1[Reference]	0.99 (0.91, 1.08)	1.62 (1.05, 2.50)	0.97 (0.82, 1.16)	0.97 (0.91, 1.04)	1.06 (0.97, 1.15)
Multivariable RR (95% CI)[b]	1[Reference]	0.95 (0.87, 1.04)	1.46 (0.94, 2.25)	0.90 (0.75, 1.08)	0.93 (0.87, 1.00)	0.98 (0.90, 1.07)
Combined						

Cases, No. (N=23623)	7244	3658	568	1308	5216	5629
Age-adjusted RR (95% CI)	1[Reference]	1.05 (1.01, 1.09)	1.06 (0.97, 1.15)	1.05 (0.99, 1.12)	1.04 (1.00, 1.08)	1.04 (1.00, 1.08)
Multivariable RR (95% CI)[b]	1[Reference]	1.02 (0.98, 1.06)	1.00 (0.92, 1.10)	1.01 (0.95, 1.07)	1.00 (0.97, 1.04)	0.99 (0.96, 1.03)

NHS 1986-2012, HPFS 1998-2010

[a]For prostate cancer, only advanced cases were included.

[b]Adjusted for the same variables as in Table 2.

[c]Never regular user was defined as nonregular user (<2 times/wk) on the most recent questionnaire and on all previous questionnaires.

eTable 7. Joint Analysis of Dose and Duration of Regular Aspirin Use and Risk for Cancer

	Dose (tablets/wk)	Years of Any Aspirin Use				
		0	1-5	6-10	11-15	≥16
Total cancer[a,b]						
Women	0	6307				
		1[Reference]				
	0.5-1.5		263	344	154	381
			1.07 (0.94, 1.21)	1.15 (1.03, 1.29)	1.02 (0.87, 1.20)	0.94 (0.85, 1.05)
	2-5		785	920	525	1468
			1.00 (0.92, 1.08)	0.99 (0.93, 1.07)	1.02 (0.93, 1.11)	0.94 (0.88, 1.00)
	≥6		541	743	469	1458
			1.00 (0.92, 1.10)	0.97 (0.90, 1.05)	1.04 (0.94, 1.14)	0.98 (0.92, 1.04)
Men	0	2432				
		1[Reference]				
	0.5-1.5		112	188	110	161
			0.91 (0.75, 1.11)	0.93 (0.80, 1.09)	0.87 (0.71, 1.07)	1.01 (0.85, 1.20)
	2-5		217	420	261	359
			0.98 (0.85, 1.14)	0.93 (0.83, 1.04)	0.94 (0.82, 1.08)	0.99 (0.87, 1.12)
	≥6		128	330	242	310
			0.85 (0.71, 1.03)	0.88 (0.78, 1.00)	0.88 (0.76, 1.01)	0.92 (0.81, 1.05)
Combined	0	8739				
		1[Reference]				
	0.5-1.5		375	532	264	542
			1.02 (0.92, 1.14)	1.08 (0.98, 1.18)	0.97 (0.85, 1.10)	0.97 (0.88, 1.06)
	2-5		1002	1340	786	1827
			1.00 (0.93, 1.07)	0.98 (0.92, 1.04)	1.00 (0.93, 1.08)	0.95 (0.90, 1.00)
	≥6		669	1073	711	1768
			0.98 (0.90, 1.06)	0.95 (0.89, 1.02)	0.99 (0.91, 1.07)	0.97 (0.92, 1.02)
GI cancer[b]						
Women	0	840				
		1[Reference]	25	37	15	37
	0.5-1.5		0.78 (0.52, 1.17)	0.96 (0.68, 1.34)	0.75 (0.45, 1.26)	0.74 (0.53, 1.04)
			84	101	50	152
	2-5		0.81 (0.64, 1.02)	0.88 (0.71, 1.09)	0.75 (0.56, 1.01)	0.82 (0.68, 0.98)
			67	91	54	137
	≥6		0.86 (0.67, 1.11)	0.86 (0.69, 1.07)	0.84 (0.63, 1.11)	0.70 (0.58, 0.85)
Men						
	0	655				
		1[Reference]				
	0.5-1.5		31	45	23	33
			1.03 (0.71, 1.51)	0.93 (0.67, 1.28)	0.69 (0.45, 1.08)	0.77 (0.53, 1.12)
	2-5		60	86	61	86
			1.11 (0.83, 1.47)	0.74 (0.58, 0.94)	0.86 (0.65, 1.14)	0.93 (0.71, 1.20)
	≥6		31	86	53	76

			0.82 (0.56, 1.21)	0.88 (0.69, 1.12)	0.72 (0.53, 0.97)	0.85 (0.65, 1.10)
Combined	0	1495				
		1[Reference]				
	0.5-1.5		56	82	38	70
			0.90 (0.68, 1.18)	0.93 (0.74, 1.18)	0.71 (0.51, 0.99)	0.75 (0.58, 0.96)
	2-5		144	187	111	238
			0.91 (0.76, 1.09)	0.80 (0.68, 0.94)	0.80 (0.66, 0.98)	0.85 (0.73, 0.99)
	≥6		98	177	107	213
			0.85 (0.69, 1.04)	0.86 (0.73, 1.02)	0.77 (0.63, 0.94)	0.75 (0.64, 0.87)

NHS 1980-2012, HPFS 1992-2010

[a]For prostate cancer, only advanced cases were included.

[b]Adjusted for the same variables as in Table 2.

eTable8. Population-Attributable Risk (PAR) of Regular Aspirin Use

	Cases, No.	PAR (95% CI), %
Total cancer		
Women	20414	1.1 (0.0, 3.7)
Men	7571	3.1 (1.0, 5.3)
Combined	27985	1.8 (0.6, 3.1)
GI cancer		
Women	2376	7.4 (3.3, 11.5)
Men	1917	8.6 (4.8, 12.4)
Combined	4293	8.0 (5.4, 10.6)
Colorectal cancer		
Women	1728	9.4 (4.8, 14.1)
Men	1167	12.6 (8.0, 17.1)
Combined	2895	10.8 (7.8, 13.7)
Sigmoidoscopy/colonoscopy[a]		
Yes	1099	8.5 (3.9, 12.9)
No	1120	17.0 (12.8, 21.1)

[a]Restricted to age 50 and above.

eFigure. Stratified Analysis of Regular Aspirin Use and Risk for Gastrointestinal and Colorectal Cancer

A. Gastrointestinal cancer

B. Colorectal cancer

A.



B.